<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381899</url>
  </required_header>
  <id_info>
    <org_study_id>BR-1</org_study_id>
    <nct_id>NCT02381899</nct_id>
  </id_info>
  <brief_title>Observational Study in CLL Patients Receiving BR</brief_title>
  <official_title>Observational Study in Chronic Lymphocytic Leukemia Patients Receiving Bendamustine and Rituximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Czech CLL Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Czech CLL Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to provide additional data to confirm the safety
      profile and efficacy of bendamustine and rituximab (BR) chemotherapy for chronic lymphocytic
      leukemia patients treated in routine clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BR (bendamustine, rituximab) combination is currently accepted as a first-line treatment of
      chronic lymphocytic leukemia (CLL) in patients for whom fludarabine combination chemotherapy
      is not appropriate.

      The objective of this observational study is to provide additional data to confirm the safety
      profile and efficacy of BR for CLL patients treated in routine clinical practice.

      Specific data of interest are: comorbid conditions, CLL characteristics, adverse events,
      reasons for discontinuation BR, overall response rates, complete response rate,
      progression-free survival, overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity assessed by Common Toxicity Criteria for Adverse Effects (CTCAE) criteria</measure>
    <time_frame>8 months</time_frame>
    <description>Toxicity assessed by Common Toxicity Criteria for Adverse Effects (CTCAE) criteria (myelotoxicity, infections, etc.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>BR in CLL</arm_group_label>
    <description>Patients receive bendamustine hydrochloride 90mg/m2 IV on days 1 and 2 each cycle. Patients also receive rituximab 375 mg/m2 IV on day 1 at first cycle and 500 mg/m2 on day 1 all subsequent cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine and Rituximab</intervention_name>
    <description>Patients receive bendamustine and rituximab. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
    <arm_group_label>BR in CLL</arm_group_label>
    <other_name>Mabthera</other_name>
    <other_name>Levact</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic lymphocytic leukemia.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of chronic lymphocytic leukemia

          -  Patients treated with BR for active disease requiring treatment

          -  Informed consent to data collection

        Exclusion Criteria:

          -  Patients treated with BR within prospective clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Spacek, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Czech CLL Study Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Spacek, MD, PhD</last_name>
    <phone>+420224966414</phone>
    <email>m.spacek@centrum.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology - Oncology, University Hospital</name>
      <address>
        <city>Brno</city>
        <zip>60500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Doubek, Prof,MD,PhD</last_name>
      <phone>+420532231111</phone>
      <email>mdoubek@fnbrno.cz</email>
    </contact>
    <investigator>
      <last_name>Michael Doubek, Prof,MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>4th Department of Medicine - Hematology, University Hospital</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lukas Smolej, MD, PhD</last_name>
      <phone>+420495832649</phone>
      <email>lukas.smolej@fnhk.cz</email>
    </contact>
    <investigator>
      <last_name>Lukas Smolej, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hemato-Oncology, University Hospital</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renata Urbanova, M.D.</last_name>
      <phone>+420 588 441 111</phone>
      <email>Renata.Urbanova@fnol.cz</email>
    </contact>
    <investigator>
      <last_name>Renata Urbanova, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, University Hospital</name>
      <address>
        <city>Plzen</city>
        <zip>30599</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Lysak, M.D. Ph.D.</last_name>
      <phone>+420 377 401 111</phone>
      <email>lysak@fnplzen.cz</email>
    </contact>
    <investigator>
      <last_name>Daniel Lysak, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine - Hematology, University Hospital Kralovske Vinohrady</name>
      <address>
        <city>Praha</city>
        <zip>10034</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lubica Zikavska, M.D.</last_name>
      <phone>+420 267 16 1111</phone>
      <email>lubica.zikavska@fnkv.cz</email>
    </contact>
    <investigator>
      <last_name>Lubica Zikavska, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>1st Department of Medicine - Hematology, General University Hospital</name>
      <address>
        <city>Praha</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Spacek, MD, PhD</last_name>
      <phone>+420224966414</phone>
      <email>m.spacek@centrum.cz</email>
    </contact>
    <investigator>
      <last_name>Martin Spacek, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petra Obrtlikova, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for Hematology and Blood Transfusion</name>
      <address>
        <city>Praha</city>
        <zip>12820</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiri Schwarz, M.D. Ph.D.</last_name>
      <phone>+420 221 977 111</phone>
      <email>jiri.schwarz@uhkt.cz</email>
    </contact>
    <investigator>
      <last_name>Jiri Schwarz, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <link>
    <url>http://www.cll.cz</url>
    <description>Czech CLL Study Group</description>
  </link>
  <reference>
    <citation>Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, Pflüger KH, Schott S, Goede V, Isfort S, von Tresckow J, Fink AM, Bühler A, Winkler D, Kreuzer KA, Staib P, Ritgen M, Kneba M, Döhner H, Eichhorst BF, Hallek M, Stilgenbauer S, Wendtner CM. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012 Sep 10;30(26):3209-16. doi: 10.1200/JCO.2011.39.2688. Epub 2012 Aug 6.</citation>
    <PMID>22869884</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>bendamustine</keyword>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

